- Previous Close
28.60 - Open
27.60 - Bid 27.40 x --
- Ask 27.80 x --
- Day's Range
27.60 - 27.60 - 52 Week Range
26.80 - 56.50 - Volume
50 - Avg. Volume
28 - Market Cap (intraday)
5.131B - Beta (5Y Monthly) 1.37
- PE Ratio (TTM)
-- - EPS (TTM)
-3.28 - Earnings Date May 6, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline includes RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
www.revmed.comRecent News: 42Z.F
View MorePerformance Overview: 42Z.F
Trailing total returns as of 4/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 42Z.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 42Z.F
View MoreValuation Measures
Market Cap
5.31B
Enterprise Value
3.34B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.56
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-18.66%
Return on Equity (ttm)
-29.33%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-600.09M
Diluted EPS (ttm)
-3.28
Balance Sheet and Cash Flow
Total Cash (mrq)
2.29B
Total Debt/Equity (mrq)
6.00%
Levered Free Cash Flow (ttm)
-347.69M